Patents
US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026
0 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Insight Molecular Diagnostics Inc.’s names, not what it holds today.
Patents granted
0
by type: not read, 1976 to Dec 31, 2025
Granted in 2025
none
in the last year the record reads
Applications published
10
1 of them in 2025
Names they are printed under
2
a former name
By yearGrantedApplications published
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
Under which name2 counted
Oncocyte Corporation a former name
named as the applicant on its applications, in US
6 publishedOncocyte Corporation a former name
US, as the owner printed on each patent
4 published
Newest applications publishedan application is a clue, never a plan
| Published | Application | Title | Field | Owner as printed |
|---|
| May 1, 2025 | 2025/0140406 | CLASSIFYING TUMORS AND PREDICTING RESPONSIVENESS | Computer technology | Oncocyte Corporation |
| Sep 21, 2023 | 2023/0296584 | CLASSIFYING TUMORS AND PREDICTING RESPONSIVENESS | Biotechnology | Oncocyte Corporation |
| Sep 15, 2022 | 2022/0291220 | METHODS AND COMPOSITIONS FOR DETECTION AND TREATMENT OF LUNG CANCER | Analysis of biological materials | Oncocyte Corporation |
| Jan 15, 2015 | 2015/0018235 | Methods and Compositions for the Treatment and Diagnosis of Pancreatic Cancer | Analysis of biological materials | Oncocyte Corporation |
| Dec 4, 2014 | 2014/0357518 | Methods and Compositions for the Treatment and Diagnosis of Thyroid Cancer | Analysis of biological materials | Oncocyte Corporation |
| Oct 30, 2014 | 2014/0323342 | Methods and Compositions for the Treatment and Diagnosis of Bladder Cancer | Analysis of biological materials | Oncocyte Corporation |
| Aug 21, 2014 | 2014/0235486 | Methods and Compositions for the Treatment and Diagnosis of Breast Cancer | Analysis of biological materials | Oncocyte Corporation |
| Jun 5, 2014 | 2014/0154691 | Methods and Compositions for the Treatment and Diagnosis of Bladder Cancer | Analysis of biological materials | Oncocyte Corporation |
| May 22, 2014 | 2014/0141996 | Methods and Compositions for the Treatment and Diagnosis of Cancer | Analysis of biological materials | Oncocyte Corporation |
| Nov 7, 2013 | 2013/0295581 | Methods and Compositions for the Treatment and Diagnosis of Breast Cancer | Analysis of biological materials | Oncocyte Corporation |
What it applied for, 2024 to 2025: Computer technology 1.
A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.